Dr Yuri Martina
Ted Suh
Ted is a medicinal chemist with extensive experience in pharmaceutical drug discovery and development. He has held various leadership positions in pharma, including at Glaxo and Eisai, contributing to the discovery of several clinical candidates in the areas of metabolic disease, oncology and autoimmune diseases. His expertise ranges from combinatorial chemistry to drug discovery using complex molecules like natural products. At Orionis, his attention has turned to the discovery and optimization of molecular glues, with a special focus on the evolution of chemistries for a diverse range of monovalent types of glues. Ted received a B.A. degree in chemistry from Yale University and a Ph.D. degree in chemistry from Harvard University.
Scott Parkinson
Leah Ramoutar
Leah is the Head of TCFD at Phoenix Group where she oversees all the Group’s activities related to climate risk and leads on a number of ESG, climate and nature-related projects. Prior to joining Phoenix in 2009, Leah spent two years in Investment Management and five years in the audit and corporate finance advisory practice at KPMG. Leah started her career in sustainable finance, working with SME clients across the Caribbean and South America. She holds a B.Sc. in Business Management from King’s College, London and is a Fellow Chartered Accountant.
Chris Sloas
Chris is a Scientist at Carisma Therapeutics. He leads research focused on applying gene editing, protein engineering, and synthetic biology techniques to expand the therapeutic applications of Carisma’s CAR-Macrophage platform. Prior to joining Carisma, Chris obtained his PhD from Boston University, where he developed molecular tools to control cellular mechanosensation.
Danielle Gregor
As a Clinical Applications Manager for the Northeast Region of the US, Dr. Gregor is responsible for all aspects of Miltenyi Biotec’s clinical portfolio, including clinical reagents, instrumentation and services. Her focus is on providing academic institutions and hospitals scientific and technical expertise for graft engineering and cell and gene therapy. She has been in the field of Cellular Therapy and Tissue Engineering for 10 years. Prior to joining Miltenyi, Danielle completed her multidisciplinary PhD in Cell Biology, Neuroscience and Physiology from Rutgers New Jersey Medical School. She also worked as a Research Associate at Celgene and as a Technical Support Specialist with PromoCell.
Monica Mallampalli
